Thyroid diagnostics has come a long way, with advances in immunoassay technologies enabling increasingly sensitive and reliable measurements across a broad range of thyroid biomarkers.
From TSH, T3, and T4 testing for thyroid function assessment to thyroglobulin (Tg) monitoring in thyroid cancer and autoantibody detection in autoimmune thyroid diseases, these developments continue to support clinical decision-making.
As thyroid testing evolves, Hytest supports assay developers with a broad portfolio of monoclonal antibodies and antigens for key thyroid biomarkers, offering reagent options for different assay designs and applications.
TSH remains the primary biomarker for assessing thyroid function, while T3 and T4 measurements provide additional insights into thyroid hormone status.
Improvements in immunoassay sensitivity have made it possible to detect increasingly low TSH concentrations, supporting the assessment of thyroid dysfunction.
Hytest provides monoclonal antibodies for TSH (Cat. # 2TS11/2TS11cc), T3 (Cat. # 2T7), and T4 (Cat. # 2T6) assay development, alongside recombinant human TSH antigen (Cat. # 8HTS7). Produced in mammalian cells, the antigen contains both the α- and β-subunits of human TSH, closely resembling its native heterodimeric structure. With a purity of ≥95%, it offers a well-characterized reagent option for TSH immunoassay development, calibration, and assay optimization.
Thyroglobulin (Tg) is an important biomarker for monitoring patients with differentiated thyroid cancer, particularly following thyroidectomy.
While modern immunoassays enable highly sensitive Tg measurements, interference from endogenous thyroglobulin autoantibodies (TgAb) remains an important consideration, as it can lead to falsely low Tg results.
Hytest offers monoclonal antibodies for sensitive Tg detection under Cat. # 2TG12cc. In prototype chemiluminescence immunoassays (CLIA), recommended antibody pairs achieved a limit of detection (LoD) of ≤0.02 ng/mL, with selected combinations demonstrating low or no detectable TgAb interference under the evaluated conditions.
These results support the development of sensitive Tg assays with reduced susceptibility to autoantibody interference.
Thyroid autoantibodies, particularly TgAb and anti-TPO, are important markers in autoimmune thyroid diseases.
Hytest offers MAbs for competitive anti-Tg assay development, including TG08, TG51, TG61, and TG66. In prototype evaluations, combining TG08 or TG61 with TG66 at a 3:1 ratio improved correlation with a commercial anti-Tg assay (R² > 0.9).
Our portfolio also includes native and recombinant thyroglobulin antigens (Cat. # 8TG52 and 8RTG4), together with recombinant TPO antigen (Cat. # 8RTP0) and TPO MAbs (Cat. # 4TP15), offering reagent options for different autoantibody assay configurations.
From routine thyroid function assessment to thyroid cancer monitoring and autoimmune disease testing, Hytest provides a broad selection of antibodies and antigens to support evolving assay development needs.
For further information about the thyroid portfolio, please visit the Hytest thyroid diseases product category, or explore our Thyroid Diseases brochure for detailed product information, performance data, and recommended antibody combinations.
For details, please contact the Hytest Sales team to discuss suitable reagents for your applications.